Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$27.97M+67.0%$16.74M+93.9%$8.64M-48.8%$16.88M
$18.11M+32.6%$13.66M+1.7%$13.44M-16.2%$16.03M
$46.08M+51.6%$30.4M+37.7%$22.07M-32.9%$32.91M
$7.14M+37.0%$5.21M+58.8%$3.28M-6.1%$3.49M
-$38.95M-54.5%-$25.2M-34.0%-$18.8M+36.1%-$29.43M
$1K0.0%$1K0.0%$1K0.0%$1K
-$38.95M-54.5%-$25.2M-34.0%-$18.8M+36.1%-$29.43M+43.6%-$52.19M+17.3%
-$38.63M-55.2%-$24.88M-34.2%-$18.54M+36.6%-$29.22M
-$38.95M-54.5%-$25.2M-34.0%-$18.8M+36.1%-$29.43M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is LB Pharmaceuticals Inc Common Stock profitable?
LB Pharmaceuticals Inc Common Stock is not currently profitable: it reported a net loss of $39.0M over the trailing twelve months.
What is LB Pharmaceuticals Inc Common Stock's earnings per share?
LB Pharmaceuticals Inc Common Stock's diluted EPS over the trailing twelve months is $-30.07.
Where does LB Pharmaceuticals Inc Common Stock's income statement data come from?
Every line is extracted from LB Pharmaceuticals Inc Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.